Herriot Tabuteau files Form 144 planned sale of AXSM worth $12.2MHerriot Tabuteau 提交 Form 144，计划减持 Axsome Therapeutics, Inc. (AXSM) $12.2M
Planned Sale Disclosure Details
On June 9, 2026, Herriot Tabuteau, CEO, director, and 10% beneficial owner of Axsome Therapeutics (ticker: AXSM), filed a Form 144 with the SEC indicating a planned sale of 49,670 common shares, with an aggregate market value of $12,200,938.80. The proposed sale date matches the filing date of June 9, 2026. This advance disclosure alerts market participants to potential future equity supply, rather than confirming an executed stock sale.
Significance of Form 144 Filing
Form 144 is a mandatory pre-disclosure filing required by the SEC for affiliates and insiders intending to sell company stock. The filing only communicates a proposed transaction intent, not an already completed sale. Actual execution of the sale will only be confirmed via a subsequent Form 4 filing submitted after the trade is finalized.
Relevant Context
This disclosure aligns with other SEC filings made on June 9, 2026: Herriot Tabuteau also submitted multiple Form 4 documents that day, including one executed sale of 49,670 shares at $241.01 per share (valued at $11,970,967) and two exempt sale records. Additionally, as of December 31, 2025, AXSM had 420 institutional holders owning 75.2% of its float, an increase of 40 institutional investors from prior periods. Analyst ratings have remained stable over the past three months, with no sell or strong sell ratings issued.
What This Signal Does Not Prove
First, this planned sale disclosure is not investment advice and does not imply any specific price movement for AXSM stock. Second, the proposed sale may be driven solely by personal portfolio diversification or short-term liquidity needs, and does not reflect a negative view of the company’s long-term prospects. Third, the filing does not guarantee the sale will be completed; final execution of the trade will require a subsequent Form 4 update to confirm.
拟出售披露详情
2026年6月9日，Axsome Therapeutics（股票代码：AXSM）的首席执行官兼董事、10%受益大股东Herriot Tabuteau向美国SEC提交Form 144文件，计划出售49,670股公司普通股，总市值达12,200,938.80美元，拟出售日期与文件提交日期一致。这一预先披露将向市场参与者提示潜在的未来股票供应情况，而非已完成的股票抛售。
Form 144的披露意义
Form 144是美国证券交易委员会要求的关联方、内部人士拟出售股票的法定预先披露文件，仅代表计划中的交易意向，并非已完成的实际销售。只有当内部人士实际完成出售后，才需提交Form 4文件确认交易细节和执行情况。
相关背景信息
本次披露与当日其他SEC filings形成联动：2026年6月9日，Herriot Tabuteau同时提交了多份Form 4文件，其中包括一笔已完成的49,670股出售交易（每股241.01美元，市值约11,970,967美元），以及两笔豁免销售记录。此外，截至2025年12月31日，AXSM共有420家机构投资者持有其75.2%的流通股，较此前增加了40家机构；近三个月分析师评级分布保持稳定，无卖出或强力卖出评级。
该信号不证明的内容
首先，本次拟出售披露并非投资建议，无法推断股票价格将出现特定波动；其次，该计划出售可能仅用于个人资产多元化或短期流动性需求，不代表内部人士对公司长期前景的负面判断；第三，该披露不确认实际出售一定会执行，最终交易是否完成需等待后续Form 4文件的更新披露。
This analysis was generated by InvestLog AI based on SEC filings, Form 4 insider transactions, Form 144 planned-sale notices, 13F institutional holdings, analyst ratings, and market data. It is for informational purposes only and does not constitute investment advice.这篇研究由 InvestLog AI 基于 SEC 披露、Form 4 内部人交易、Form 144 计划减持、13F 机构持仓、分析师评级和市场数据生成。内容仅供参考，不构成投资建议。